X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (94035) 94035
Newsletter (9042) 9042
Newspaper Article (6550) 6550
Magazine Article (137) 137
Book / eBook (64) 64
Book Chapter (64) 64
Web Resource (16) 16
Dissertation (8) 8
Conference Proceeding (7) 7
Publication (7) 7
Reference (4) 4
Transcript (4) 4
Government Document (3) 3
Streaming Video (3) 3
Paper (2) 2
Book Review (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (80351) 80351
oncology (44608) 44608
female (40355) 40355
lung neoplasms - drug therapy (38882) 38882
male (37004) 37004
cancer (33712) 33712
lung cancer (30837) 30837
middle aged (29628) 29628
aged (26299) 26299
chemotherapy (22859) 22859
lung neoplasms - pathology (20746) 20746
research (20257) 20257
adult (20228) 20228
animals (20036) 20036
carcinoma, non-small-cell lung - drug therapy (18802) 18802
care and treatment (16556) 16556
lung cancer, non-small cell (15915) 15915
antineoplastic combined chemotherapy protocols - therapeutic use (13991) 13991
cell line, tumor (13975) 13975
mice (13111) 13111
antineoplastic agents - therapeutic use (12661) 12661
metastasis (11978) 11978
tumors (11913) 11913
treatment outcome (11423) 11423
prognosis (10855) 10855
lung neoplasms - genetics (10391) 10391
apoptosis (10295) 10295
lung-cancer (10028) 10028
oncology, experimental (10018) 10018
carcinoma, non-small-cell lung - pathology (9932) 9932
cell lung-cancer (9913) 9913
cancer therapies (9712) 9712
lung neoplasms - metabolism (8565) 8565
analysis (8546) 8546
aged, 80 and over (8486) 8486
mutation (8270) 8270
expression (8256) 8256
health aspects (7910) 7910
neoplasm staging (7755) 7755
antineoplastic agents - pharmacology (7730) 7730
lung neoplasms - secondary (7614) 7614
respiratory system (7122) 7122
genetic aspects (6971) 6971
survival (6970) 6970
lung neoplasms - mortality (6929) 6929
drug therapy (6913) 6913
pharmacology & pharmacy (6874) 6874
neoplasms - drug therapy (6551) 6551
lung cancer, small cell (6481) 6481
therapy (6425) 6425
cisplatin (6066) 6066
carcinoma (6019) 6019
carcinoma, non-small-cell lung - genetics (5925) 5925
proteins (5827) 5827
combined modality therapy (5727) 5727
breast-cancer (5568) 5568
gene expression (5476) 5476
patients (5450) 5450
retrospective studies (5449) 5449
cisplatin - administration & dosage (5303) 5303
kinases (5279) 5279
radiotherapy (5270) 5270
lung neoplasms - therapy (5268) 5268
adenocarcinoma - drug therapy (5247) 5247
survival rate (5155) 5155
non-small cell lung cancer (5140) 5140
immunotherapy (5133) 5133
apoptosis - drug effects (5032) 5032
survival analysis (5006) 5006
gefitinib (4924) 4924
breast cancer (4923) 4923
surgery (4901) 4901
medicine (4890) 4890
clinical trials (4861) 4861
medical research (4848) 4848
cell biology (4834) 4834
lung neoplasms - radiotherapy (4777) 4777
medicine & public health (4726) 4726
development and progression (4663) 4663
mice, nude (4634) 4634
antineoplastic combined chemotherapy protocols - adverse effects (4595) 4595
cell proliferation - drug effects (4554) 4554
antineoplastic agents (4500) 4500
hematology, oncology and palliative medicine (4425) 4425
medical prognosis (4415) 4415
carcinoma, non-small-cell lung - mortality (4236) 4236
research article (4236) 4236
biochemistry & molecular biology (4202) 4202
carcinoma, small cell - drug therapy (4192) 4192
dose-response relationship, drug (4139) 4139
adenocarcinoma (4138) 4138
neoplasm metastasis (4071) 4071
studies (4028) 4028
risk factors (4025) 4025
disease-free survival (3991) 3991
antimitotic agents (3986) 3986
epidermal growth factor (3981) 3981
physical fitness (3954) 3954
antineoplastic agents - administration & dosage (3927) 3927
lung neoplasms - surgery (3860) 3860
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (16) 16
Gerstein Science - Stacks (15) 15
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (6) 6
St. Michael's Hospital - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Providence Healthcare - Reference (2) 2
West Park Healthcare Centre - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Humber River Regional Hospital - Church Reference (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
New College (Ivey) - Stacks (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - General (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (104108) 104108
Japanese (2664) 2664
Chinese (1407) 1407
French (1200) 1200
German (836) 836
Russian (476) 476
Italian (294) 294
Spanish (234) 234
Polish (205) 205
Hungarian (74) 74
Dutch (52) 52
Danish (51) 51
Czech (42) 42
Portuguese (40) 40
Romanian (33) 33
Swedish (20) 20
Korean (18) 18
Turkish (16) 16
Croatian (15) 15
Finnish (14) 14
Serbian (13) 13
Ukrainian (12) 12
Norwegian (11) 11
Hebrew (8) 8
Lithuanian (7) 7
Bulgarian (4) 4
Slovak (3) 3
Bosnian (2) 2
Arabic (1) 1
Greek (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Seminars in Oncology, ISSN 0093-7754, 2015, Volume 42, Issue 6, pp. 801 - 819
.... Most of these molecular alterations promote multiple steps of carcinogenesis in FGFR oncogene-addicted cells, increasing cell proliferation, angiogenesis, and drug resistance... 
BREAST-CANCER | LUNG-CANCER | IN-VITRO | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | RESISTANCE | GENE AMPLIFICATION | POTENTIAL THERAPEUTIC TARGET | PROGNOSTIC-SIGNIFICANCE | ANTITUMOR-ACTIVITY | EXPRESSION | Neoplasms - metabolism | Gastrointestinal Neoplasms - genetics | Gastrointestinal Neoplasms - drug therapy | Humans | Brain Neoplasms - pathology | Fibroblast Growth Factors - genetics | Brain Neoplasms - metabolism | Head and Neck Neoplasms - metabolism | Breast Neoplasms - metabolism | Fibroblast Growth Factors - metabolism | Gastrointestinal Neoplasms - pathology | Glioblastoma - genetics | Receptors, Fibroblast Growth Factor - genetics | Female | Glioblastoma - metabolism | Antineoplastic Agents - pharmacology | Molecular Targeted Therapy - methods | Gastrointestinal Neoplasms - metabolism | Biomarkers, Tumor - analysis | Head and Neck Neoplasms - drug therapy | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Thoracic Neoplasms - pathology | Brain Neoplasms - genetics | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Thoracic Neoplasms - metabolism | Head and Neck Neoplasms - pathology | Neoplasms - drug therapy | Breast Neoplasms - genetics | Thoracic Neoplasms - genetics | Breast Neoplasms - pathology | Glioblastoma - pathology | Receptors, Fibroblast Growth Factor - metabolism | Head and Neck Neoplasms - genetics | Fibroblast Growth Factors - antagonists & inhibitors | Thoracic Neoplasms - drug therapy | Glioblastoma - drug therapy | Neoplasms - pathology | Drug Resistance, Neoplasm - physiology | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
Journal Article
EMBO molecular medicine, ISSN 1757-4684, 2014, Volume 6, Issue 10, pp. 1279 - 1293
Epithelial‐mesenchymal transition (EMT) is a reversible and dynamic process hypothesized to be co‐opted by carcinoma during invasion and metastasis. Yet, there... 
drug response | microarray | gene expression signature | epithelial‐mesenchymal transition | prognosis | Drug response | Epithelial-mesenchymal transition | Prognosis | Microarray | Gene expression signature | MOLECULAR SUBTYPES | MEDICINE, RESEARCH & EXPERIMENTAL | GENE-EXPRESSION SIGNATURE | STEM-CELLS | GENOMIC ANALYSES | OVARIAN-CANCER | NEGATIVE BREAST-CANCER | CLINICAL-RELEVANCE | MICRORNA CONTROL | CLAUDIN-LOW | epithelial-mesenchymal transition | SIGNATURE PREDICTS RESISTANCE | Lung Neoplasms - drug therapy | Oligonucleotide Array Sequence Analysis | Colorectal Neoplasms - genetics | Humans | Epithelial-Mesenchymal Transition - drug effects | Antineoplastic Agents - therapeutic use | Epithelial-Mesenchymal Transition - genetics | Ovarian Neoplasms - genetics | Urinary Bladder Neoplasms - genetics | Neoplasms - genetics | Colorectal Neoplasms - drug therapy | Female | Gene Expression Regulation, Neoplastic - drug effects | Ovarian Neoplasms - drug therapy | Lung Neoplasms - genetics | Stomach Neoplasms - genetics | Treatment Outcome | Transcriptome - drug effects | Transcriptome - genetics | Stomach Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - genetics | Cell Line, Tumor | Cancer patients | Chemotherapy | Patient outcomes | Stem cells | Development and progression | Drug therapy | Gene expression | Ovarian cancer | Cancer | Mesenchyme | Colorectal carcinoma | Genomes | Breast cancer | Metastasis | Kinases | Cancer therapies | Metastases | Breast carcinoma | Genotype & phenotype | Paclitaxel | Breast | Software | Tumors
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2011, Volume 81, Issue 1, pp. 126 - 134
Purpose To perform a comprehensive cognitive function (CF) assessment in patients who were relapse free after curative intent radiotherapy (RT... 
Radiology | Hematology, Oncology and Palliative Medicine | Squamous cell carcinoma of the head and neck | Chemotherapy | Neuropsychological testing | Radiotherapy | Cognitive dysfunction | PROPHYLACTIC CRANIAL IRRADIATION | ADJUVANT CHEMOTHERAPY | DRIVING PERFORMANCE | FOLLOW-UP | CELL LUNG-CANCER | BREAST-CANCER | NASOPHARYNGEAL CARCINOMA | ONCOLOGY | NEUROCOGNITIVE FUNCTION | LOW-GRADE GLIOMA | QUALITY-OF-LIFE | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Laryngeal Neoplasms - radiotherapy | Pharyngeal Neoplasms - radiotherapy | Cerebellum - radiation effects | Prospective Studies | Humans | Middle Aged | Male | Pharyngeal Neoplasms - drug therapy | Antineoplastic Agents - administration & dosage | Cognition - physiology | Laryngeal Neoplasms - drug therapy | Neoplasms, Squamous Cell - pathology | Carcinoma - drug therapy | Carcinoma - blood | Affect - physiology | Head and Neck Neoplasms - drug therapy | Cognition - drug effects | Neoplasms, Squamous Cell - blood | Head and Neck Neoplasms - pathology | Carcinoma, Squamous Cell | Neuropsychological Tests | Cognition Disorders - diagnosis | Memory Disorders - etiology | Hypopharyngeal Neoplasms - pathology | Quality of Life | Pharyngeal Neoplasms - pathology | Hypopharyngeal Neoplasms - drug therapy | Temporal Lobe - drug effects | Laryngeal Neoplasms - blood | Cerebellum - drug effects | Hypopharyngeal Neoplasms - blood | Cisplatin - administration & dosage | Feasibility Studies | Laryngeal Neoplasms - pathology | Squamous Cell Carcinoma of Head and Neck | Head and Neck Neoplasms - blood | Antineoplastic Agents - adverse effects | Cognition Disorders - etiology | Neoplasms, Squamous Cell - drug therapy | Neoplasms, Squamous Cell - radiotherapy | Female | Carcinoma - pathology | Cognition - radiation effects | Affect - drug effects | Pharyngeal Neoplasms - blood | Affect - radiation effects | Carcinoma - radiotherapy | Combined Modality Therapy - adverse effects | Head and Neck Neoplasms - radiotherapy | Hypopharyngeal Neoplasms - radiotherapy | Cisplatin - adverse effects | Aged | Combined Modality Therapy - methods | Temporal Lobe - radiation effects | Care and treatment | Squamous cell carcinoma | Cancer | BODY FLUIDS | HEAD | NERVOUS SYSTEM | RADIATION DOSES | MEDICINE | THERAPY | CEREBELLUM | RADIOLOGY AND NUCLEAR MEDICINE | RADIOTHERAPY | COMBINED THERAPY | BRAIN | RADIOLOGY | BLOOD | NEOPLASMS | BIOLOGICAL MATERIALS | CENTRAL NERVOUS SYSTEM | STANDARD OF LIVING | CHEMOTHERAPY | NUCLEAR MEDICINE | ORGANS | DISEASES | DOSES | CARCINOMAS | NECK | DOSIMETRY | BODY | MATERIALS
Journal Article
American Journal of Pathology, ISSN 0002-9440, 2010, Volume 177, Issue 4, pp. 1647 - 1656
Phosphatase and tensin homolog (PTEN) is a key modulator of trastuzumab sensitivity in HER2-overexpressing breast cancer. Because PTEN opposes the downstream... 
ADJUVANT CHEMOTHERAPY | INHIBITION | THERAPY | PROTEIN | HUMAN-BREAST-CANCER | PATHWAY | MUTATIONS | PATHOLOGY | RECEPTORS | TRASTUZUMAB RESISTANCE | EXPRESSION | Lung Neoplasms - drug therapy | Receptors, Estrogen - metabolism | Receptor, ErbB-2 - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Immunoenzyme Techniques | Receptors, Progesterone - metabolism | Young Adult | Carcinoma, Ductal, Breast - drug therapy | Brain Neoplasms - mortality | Liver Neoplasms - secondary | Proto-Oncogene Proteins c-akt - metabolism | Carcinoma, Ductal, Breast - metabolism | PTEN Phosphohydrolase - genetics | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Survival Rate | Lymphatic Metastasis | Brain Neoplasms - drug therapy | Mutation - genetics | Breast Neoplasms - drug therapy | Class I Phosphatidylinositol 3-Kinases | Carcinoma, Lobular - metabolism | Trastuzumab | Bone Neoplasms - mortality | Phosphorylation | Prognosis | Receptor, ErbB-2 - metabolism | Phosphatidylinositol 3-Kinases - metabolism | Liver Neoplasms - mortality | Carcinoma, Ductal, Breast - mortality | Carcinoma, Lobular - mortality | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Brain Neoplasms - secondary | In Situ Hybridization | Lung Neoplasms - secondary | Adult | Female | Bone Neoplasms - drug therapy | Neoplasm Invasiveness | Liver Neoplasms - drug therapy | PTEN Phosphohydrolase - metabolism | Phosphatidylinositol 3-Kinases - genetics | Breast Neoplasms - mortality | Aged | Carcinoma, Lobular - drug therapy | Regular
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 03/2013, Volume 8, Issue 3, pp. 346 - 351
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 65, Issue 2, pp. 270 - 273
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2010, Volume 28, Issue 19, pp. 3167 - 3175
Journal Article
Cancer, ISSN 0008-543X, 2017, Volume 123, Issue 11, pp. 1904 - 1911
.... To address this challenge, this review aggregates and synthesizes the available preclinical and clinical data surrounding immune checkpoint inhibitor therapy in challenging clinical... 
pembrolizumab | autoimmune | nivolumab | elderly | ipilimumab | pediatrics | pregnancy | transplant | organ dysfunction | ALLOGRAFT-REJECTION | PERFORMANCE STATUS | PD-1 BLOCKADE | OPEN-LABEL | CELL LUNG-CANCER | IPILIMUMAB THERAPY | ONCOLOGY | ADVANCED MELANOMA | BRAIN METASTASES | AUTOIMMUNE-DISEASE | T-CELLS | Lung Neoplasms - drug therapy | Melanoma - complications | Age Factors | Humans | Immunosuppressive Agents - therapeutic use | Ipilimumab | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Hepatitis C, Chronic - complications | Transplant Recipients | Neoplasms - complications | Brain Neoplasms - secondary | Squamous Cell Carcinoma of Head and Neck | Pregnancy Complications, Neoplastic - drug therapy | Female | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - complications | Graft Rejection - prevention & control | Autoimmune Diseases - complications | Head and Neck Neoplasms - drug therapy | Brain Neoplasms - drug therapy | Lung Neoplasms - complications | Neoplasms - drug therapy | Pregnancy | Carcinoma, Non-Small-Cell Lung - complications | B7-H1 Antigen - antagonists & inhibitors | Carcinoma, Squamous Cell - drug therapy | Hepatitis B, Chronic - complications | Carcinoma, Squamous Cell - complications | Melanoma - drug therapy | Nivolumab | HIV Infections - complications | Head and Neck Neoplasms - complications | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Renal Cell - complications | Immunocompromised Host | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Virus diseases | Care and treatment | Dosage and administration | Research | Cell death | Immunosuppressive agents | Medical research | Brain | Populations | Toxicity | Decision making | Mortality | Disorders | Clinical trials | Cytotoxicity | Lymphocytes T | Metastasis | Patients | Regulatory approval | Metastases | Inhibitors | Immune checkpoint | Aggregates | Lymphocytes | Safety | Autoimmune diseases | Cancer | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Cancer chemotherapy and pharmacology, ISSN 1432-0843, 2019, Volume 84, Issue 3, pp. 487 - 499
.... While their function in hepatic metabolism of taxanes is well established, expression of these enzymes in solid tumors may play a role in the in situ metabolism of drugs as well, potentially... 
Intratumoral | Ritonavir | Paclitaxel | Docetaxel | CYP | Review | Journal Article | Medicine & Public Health | Oncology | Cancer Research | Pharmacology/Toxicology | PREGNANE-X RECEPTOR | IMMUNOHISTOCHEMICAL LOCALIZATION | DOCETAXEL RESISTANCE | CYP3A4 EXPRESSION | TARGETED THERAPIES | MESSENGER-RNA | ONCOLOGY | P450-MEDIATED METABOLISM | BIOLOGICAL-ACTIVITY | PHARMACOLOGY & PHARMACY | HIV-1 PROTEASE INHIBITOR | METABOLIZING-ENZYMES | Lung Neoplasms - drug therapy | Taxoids - pharmacology | Humans | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Lung Neoplasms - pathology | Male | Breast Neoplasms - enzymology | Female | Antineoplastic Agents - pharmacology | Cytochrome P-450 CYP2C8 - metabolism | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Endometrial Neoplasms - enzymology | Lung Neoplasms - enzymology | Neoplasms - enzymology | Breast Neoplasms - drug therapy | Ovarian Neoplasms - enzymology | Neoplasms - drug therapy | Breast Neoplasms - pathology | Cytochrome P-450 CYP3A - metabolism | Prostatic Neoplasms - enzymology | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Neoplasms - pathology | Antimitotic agents | Protease inhibitors | Proteases | Pharmacy | Cytochrome P-450 | Physiological aspects | Drugstores | Antineoplastic agents | Ovarian cancer | Cytochrome | Enzymes | Cytochrome P450 | Proteinase inhibitors | Taxane | Metabolism | Anticancer properties | Antitumor agents | Lungs | Drug metabolism | Breast | Solid tumors | Taxanes | Prostate | Endometrium | Tumors | Cytochromes P450
Journal Article